Indonesian Political, Business & Finance News

Semaglutide and Ozempic: A Fourth Factor in Slowing Biological Age?

| | Source: Media Indonesia Translated from Indonesian | Technology
Semaglutide and Ozempic: A Fourth Factor in Slowing Biological Age?
Image: Media Indonesia

GLP-1 medications, such as Ozempic, were originally intended for individuals seeking weight loss and diabetes management. However, as research expands, doctors have discovered that this class of drugs may offer broader health benefits, ranging from cardiovascular health and addiction treatment to cancer therapy. The latest findings even suggest a potential reminiscent of science fiction: the slowing of biological ageing.

Scientists have recently found the first evidence that GLP-1 can indeed slow ageing at a cellular level. Biological age is considered a more accurate representation of health than chronological age. In one study, semaglutide—the active ingredient in GLP-1—was proven to help slow the accumulation of DNA markers associated with inflammation and accelerated ageing in major organs.

In a world where sleep, diet, and exercise are considered the most important pillars for maintaining healthspan, the question arises: is GLP-1 a hidden fourth factor?

A study published in Nature Communications reviewed data from trials involving adults with lipohypertrophy related to HIV, a condition that facilitates fat accumulation around the abdomen. This group often experiences accelerated biological ageing, even when the virus is well-controlled with medication.

Over a period of 32 weeks, 45 participants received weekly GLP-1 injections, while 39 others served as a control group receiving placebo injections. To determine if the injections slowed ageing, researchers compared the participants’ epigenetic clocks. This tool measures DNA methylation patterns—chemical tags that activate or deactivate genes—providing a picture of how cells in various organs are reprogrammed over time.

As a result, participants injected with semaglutide showed a slowing of biological ageing in blood cells as well as organs such as the brain, heart, liver, and kidneys. Based on the epigenetic clock, researchers estimated that semaglutide helps slow the rate of biological ageing by 9 per cent. Additionally, evidence was found of slowed expression of inflammatory markers that contribute to age-related diseases and premature death.

Another small pilot study found additional evidence. In research involving 41 individuals with HIV and fatty liver disease who received 1 milligram of weekly semaglutide, researchers observed a slowing of the biological ageing rate in 42 per cent of participants. Furthermore, nearly 49 per cent of participants had longer telomeres—the DNA caps at the ends of chromosomes that protect cells from degradation.

How could semaglutide extend longevity? There are several possible mechanisms, though it is still too early to conclude with certainty. Currently, trials are being conducted on populations with compromised immune systems. Scientists still need to evaluate whether GLP-1 has the same effect on healthy individual cells.

Larger clinical trials are required to determine whether these longevity benefits are temporary or sustainable. It will take several more years before the medical world obtains a definitive answer regarding the role of semaglutide as an anti-ageing drug.

More from 16 September 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/semaglutide-and-ozempic-a-fourth-factor-in-slowing-biological-age-1789563312)
Originally published by Media Indonesia (https://mediaindonesia.com/kesehatan/934142/semaglutide-dan-ozempic-faktor-keempat-perlambat-penuaan-biologis), translated from Indonesian
Print